# US 2019/0314292 A1 · Compounds and compositions for intracellular delivery of therapeutic agents

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0314292 A1
- Document ID: US20190314292A1
- Status: Published application
- Kind: A1
- Application number: 16/382,423
- Filed: 2019-04-12
- Published: 2019-10-17
- Earliest claimed: 2017-03-15
- Assignees: MordernaTX, Inc.
- Applicants: ModernaTX, Inc.
- Inventors: Kerry E. BENENATO; Ellalahewage Sathyajith KUMARASINGHE; Mark CORNEBISE
- Web page: https://patentgrep.com/patent/US20190314292A1

## CPC

- A61K 9/5123: {Organic compounds, e.g. fats, sugars}
- C07D 233/61: with hydrocarbon radicals, substituted by nitrogen atoms not forming part of a nitro radical, attached to ring nitrogen atoms
- A61K 9/1272: comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers (lipids as modifying agents {A61K47/543})
- A61K 38/1816: {Erythropoietin [EPO]}
- A61K 47/14: Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A61K 47/24: containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
- A61K 47/28: Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
- A61K 48/0033: {the non-active part being non-polymeric}
- C07C 219/06: having the hydroxy groups esterified by carboxylic acids having the esterifying carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C 229/08: the nitrogen atom of the amino group being further bound to hydrogen atoms
- C07C 229/12: to carbon atoms of acyclic carbon skeletons
- C07C 229/16: to carbon atoms of hydrocarbon radicals substituted by amino or carboxyl groups, e.g. ethylenediamine-tetra-acetic acid, iminodiacetic acids
- C07C 229/24: having more than one carboxyl group bound to the carbon skeleton, e.g. aspartic acid
- C07C 233/36: having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
- C07C 235/10: having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms not being part of nitro or nitroso groups
- C07C 237/06: having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C 251/38: to carbon atoms of a saturated carbon skeleton
- C07C 255/24: containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the same saturated acyclic carbon skeleton
- C07C 259/06: having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C 271/12: to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
- C07C 275/14: being further substituted by nitrogen atoms not being part of nitro or nitroso groups
- C07C 279/12: being further substituted by nitrogen atoms not being part of nitro or nitroso groups
- C07C 279/28: having nitrogen atoms of guanidine groups bound to cyano groups, e.g. cyanoguanidines, dicyandiamides
- C07C 279/36: Substituted N-nitroguanidines
- C07C 307/06: having nitrogen atoms of the sulfamide groups bound to acyclic carbon atoms
- C07C 311/05: to acyclic carbon atoms of hydrocarbon radicals substituted by nitrogen atoms, not being part of nitro or nitroso groups
- C07C 311/51: Y being a hydrogen or a carbon atom
- C07C 311/64: X and Y being nitrogen atoms, e.g. N-sulfonylguanidine
- C07C 335/08: of a saturated carbon skeleton
- C07D 239/46: Two or more oxygen, sulphur or nitrogen atoms
- C07D 249/04: 1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- C07D 295/13: to an acyclic saturated chain
- C07D 473/00: Heterocyclic compounds containing purine ring systems
- C07F 7/0814: {said ring is substituted at a C ring atom by Si}
- C07F 9/4009: {Esters containing the structure (RX)2P(=X)-alk-N...P (X = O, S, Se)}
- C07B 2200/07: Optical isomers
- C07C 2601/02: with a three-membered ring
- C07C 2601/04: with a four-membered ring
- C07C 2601/14: The ring being saturated
- C07C 2601/18: with a ring being at least seven-membered
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

The disclosure features novel lipids and compositions involving the same. Nanoparticle compositions include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Nanoparticle compositions further including therapeutic and/or prophylactics such as RNA are useful in the delivery of therapeutic and/or prophylactics to mammalian cells or organs to, for example, regulate polypeptide, protein, or gene expression.

## Claims

### Claim 1

A compound being Compound 301:
or a salt or isomer thereof.

### Claim 2 (depends on 1)

The compound of claim 1, wherein the salt is a pharmaceutically acceptable salt.

### Claim 3 (depends on 1)

A nanoparticle composition comprising a lipid component which comprises the compound of claim 1.

### Claim 4 (depends on 3)

The nanoparticle composition of claim 3, wherein the lipid component further comprises a phospholipid.

### Claim 5 (depends on 4)

The nanoparticle composition of claim 4, wherein the phospholipid is selected from the group consisting of
1,2-dilinoleoyl-sn-glycero-3-phosphocholine (DLPC),
1,2-dimyristoyl-sn-glycero-phosphocholine (DMPC),
1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC),
1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC),
1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC),
1,2-diundecanoyl-sn-glycero-phosphocholine (DUPC),
1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC),
1,2-di-O-octadecenyl-sn-glycero-3-phosphocholine (18:0 Diether PC),
1-oleoyl-2-cholesterylhemisuccinoyl-sn-glycero-3-phosphocholine (OChemsPC),
1-hexadecyl-sn-glycero-3-phosphocholine (C16 Lyso PC),
1,2-dilinolenoyl-sn-glycero-3 -phosphocholine,
1,2-diarachidonoyl-sn-glycero-3-phosphocholine,
1,2-didocosahexaenoyl-sn-glycero-3 -phosphocholine,
1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE),
1,2-diphytanoyl-sn-glycero-3-phosphoethanolamine (ME 16.0 PE),
1,2-distearoyl-sn-glycero-3-phosphoethanolamine,
1,2-dilinoleoyl-sn-glycero-3-phosphoethanolamine,
1,2-dilinolenoyl-sn-glycero-3 -phosphoethanolamine,
1,2-diarachidonoyl-sn-glycero-3-phosphoethanolamine,
1,2-didocosahexaenoyl-sn-glycero-3-phosphoethanolamine,
1,2-dioleoyl-sn-glycero-3-phospho-rac-(1-glycerol) sodium salt (DOPG),
sphingomyelin, and
mixtures thereof.

### Claim 6 (depends on 5)

The nanoparticle composition of claim 5, wherein the phospholipid is DSPC or DOPE.

### Claim 7 (depends on 4)

The nanoparticle composition of claim 4, wherein the lipid component further comprises a structural lipid.

### Claim 8 (depends on 7)

The nanoparticle composition of claim 7, wherein the structural lipid is selected from the group consisting of cholesterol, fecosterol, sitosterol, ergosterol, campesterol, stigmasterol, brassicasterol, tomatidine, ursolic acid, alpha-tocopherol, and mixtures thereof.

### Claim 9 (depends on 8)

The nanoparticle composition of claim 8, wherein the structural lipid is cholesterol.

### Claim 10 (depends on 7)

The nanoparticle compostion of claim 7, wherein the lipid component further comprises a PEG lipid.

### Claim 11 (depends on 10)

The nanoparticle composition of claim 10, wherein the PEG lipid is selected from the group consisting of a PEG-modified phosphatidylethanolamine, a PEG-modified phosphatidic acid, a PEG-modified ceramide, a PEG-modified dialkylamine, a PEG-modified diacylglycerol, a PEG-modified dialkylglycerol, and mixtures thereof.

### Claim 12 (depends on 10)

The nanoparticle composition of claim 10, wherein the lipid component comprises about 30 mol % to about 60 mol % said Compound 301, about 0 mol % to about 30 mol % phospholipid, about 18.5 mol % to about 48.5 mol % structural lipid, and about 0 mol % to about 10 mol % PEG lipid.

### Claim 13 (depends on 10)

The nanoparticle composition of claim 10, wherein the lipid component comprises about 35 mol % to about 55 mol % said Compound 301, about 5 mol % to about 25 mol % phospholipid, about 30 mol % to about 40 mol % structural lipid, and about 0 mol % to about 10 mol % PEG lipid.

### Claim 14 (depends on 10)

The nanoparticle composition of claim 10, wherein the lipid component comprises about 50 mol % said Compound 301, about 10 mol % phospholipid, about 38.5 mol % structural lipid, and about 1.5 mol % PEG lipid.

### Claim 15 (depends on 10)

The nanoparticle composition of claim 10, further comprising a therapeutic and/or prophylactic agent.

### Claim 16 (depends on 12)

The nanoparticle composition of claim 12, further comprising a therapeutic and/or prophylactic agent.

### Claim 17 (depends on 13)

The nanoparticle composition of claim 13, further comprising a therapeutic and/or prophylactic agent.

### Claim 18 (depends on 15)

The nanoparticle composition of claim 15, wherein the therapeutic and/or prophylactic agent is a nucleic acid.

### Claim 19 (depends on 15)

The nanoparticle composition of claim 15, wherein the therapeutic and/or prophylactic agent is a ribonucleic acid (RNA).

### Claim 20 (depends on 19)

The nanoparticle composition of claim 19, wherein the RNA is selected from the group consisting of a small interfering RNA (siRNA), an asymmetrical interfering RNA (aiRNA), a microRNA (miRNA), a Dicer-substrate RNA (dsRNA), a small hairpin RNA (shRNA), a messenger RNA (mRNA), and mixtures thereof.

### Claim 21 (depends on 19)

The nanoparticle composition of claim 19, wherein the RNA is mRNA.

### Claim 22 (depends on 21)

The nanoparticle composition of claim 21, wherein the mRNA includes one or more of a stem loop, a chain terminating nucleoside, a polyA sequence, a polyadenylation signal, and/or a 5′ cap structure.

### Claim 23 (depends on 21)

The nanoparticle composition of claim 21, wherein the encapsulation efficiency of the therapeutic and/or prophylactic agent is at least 80% or at least 90%.

### Claim 24 (depends on 21)

The nanoparticle composition of claim 21, wherein the wt/wt ratio of the lipid component to the mRNA is from about 10:1 to about 60:1.

### Claim 25 (depends on 21)

The nanoparticle composition of claim 21, wherein the wt/wt ratio of the lipid component to the mRNA is about 20:1.

### Claim 26 (depends on 21)

The nanoparticle composition of claim 21, wherein the N:P ratio is from about 5:1 to about 8:1.

### Claim 27 (depends on 21)

A pharmaceutical composition comprising the nanoparticle composition of claim 21 and a pharmaceutically acceptable carrier.

### Claim 28 (depends on 15)

A method of delivering a therapeutic and/or prophylactic agent to a mammalian cell, the method comprising administering to a subject the nanoparticle composition of claim 15, said administering comprising contacting the cell with the nanoparticle composition, whereby the therapeutic and/or prophylactic agent is delivered to the cell.

### Claim 29 (depends on 21)

A method of producing a polypeptide of interest in a mammalian cell, the method comprising contacting the cell with the nanoparticle composition of claim 21, wherein the mRNA encodes the polypeptide of interest, whereby the mRNA is capable of being translated in the cell to produce the polypeptide of interest.

### Claim 30 (depends on 15)

A method of treating a disease or disorder in a mammal in need thereof, the method comprising administering to the mammal a therapeutically effective amount of the nanoparticle composition of claim 15.
